Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Summary

This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Buparlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-12

Primary completion

2016-09-16

Completion

2017-03-22

Drugs

Indications